Evaluation of craving satisfaction when using a novel nicotine inhaler device
|
Author(s)
Chris Moyses, Alex Hearn and Andrew Redfern
|
| Presenter(s) |
Dr Chris Moyses Chief Medical Officer, Kind Consumer Ltd, London |
Abstract The impact of a novel nicotine inhaler device on craving satiation was assessed using a Visual Analogue Scale. Results are presented for two methodologically similar parts of a Phase I study of nicotine inhaled via the novel device (0.056% w/w; 0.45 mg nicotine) or Nicorette Inhalator (10 mg nicotine). All subjects were smoking ≥10 cigarettes/day within 1 hour of waking for ≥1 year but abstained from smoking 12 hours prior to nicotine administration on study.
Subjects (n=24/part) used the novel device (1 puff/15 sec; approx. 2 min, i.e. 8 puffs) and Nicorette Inhalator (1 puff/15 sec; max 20 min, i.e. 80 puffs) on separate days. Craving scores were lower for the novel device than the Nicorette Inhalator at most post-dose time-points; reaching significance at 180 and 240 min (first part) and at 2, 4 and 10 min (second part). In both parts, mean area under the curve was greater (indicating less effective craving reduction) for the Nicorette Inhalator versus the novel inhaler (first part: 1566.3 vs 1356.3 cm.min [p=0.029]; second part: 1402.3 vs 1208.5 cm.min [p=0.059]).
Results suggest that the novel inhaler provides superior craving relief when compared to the Nicorette Inhalator, despite lower nicotine exposure with the novel device.
|
Presenter biography Dr Chris Moyses is a pharmaceutical physician with over 25 years’ experience in drug development and clinical trials in multiple therapeutic areas.
Alex Hearn is the founder of Kind Consumer Ltd and the inventor of the novel nicotine inhaler technology.
Dr Andrew Redfern is the principal investigator at Linear Clinical Research and is a Consultant Medical Oncologist at the Royal Perth Hospital, Australia.
|
Source of funding: This study was supported by Kind Consumer Ltd. This novel inhaler is the subject of a worldwide exclusive distribution licence to Nicoventures (a wholly owned subsidiary of BAT).
|
Declaration of interest: Chris Moyses and Alex Hearn are employees of Kind Consumer Ltd. Andrew Redfern has nothing to disclose.
|
| |
